Prime Highlight
- Janux partnered with Bristol Myers Squibb to develop a new solid tumor cancer therapy, lifting its shares over 12% in premarket trade.
- The deal reflects strong demand from big pharma for innovative biotech cancer platforms.
Key Facts
- The collaboration is valued at up to $850 million, including $50 million upfront and near-term milestones plus future development and sales payments.
- Janux will complete preclinical work, while Bristol Myers Squibb will handle clinical development, regulatory approvals, and global commercialization.
Background
Janux Therapeutics on Thursday announced a major collaboration with pharmaceutical giant Bristol Myers Squibb to develop a new cancer treatment, in a deal that could be valued at up to $850 million. The announcement boosted investor confidence, with Janux shares rising more than 12% in premarket trading.
Under the agreement, Janux may receive up to $50 million in upfront and near-term milestone payments. The company is also eligible for additional payments of about $800 million, linked to progress in clinical development, regulatory approvals and future sales. If the drug successfully reaches the market, Janux will earn royalties from worldwide product sales.
The experimental therapy is designed to treat solid tumors, which include cancers that form masses in organs such as the lung, breast, colon and pancreas. According to Janux, the drug will target a tumor marker that appears across several cancer types, potentially allowing it to address a broad range of patients.
Janux will be responsible for completing preclinical testing of the therapy. After this stage, Bristol Myers Squibb will take over clinical development, regulatory work, and global commercialization. Janux will remain involved during the early phase of clinical studies, ensuring continued input into the program.
Janux Chief Executive Officer David Campbell said the partnership represents a key milestone for the company. He added that the collaboration combines Janux’s proprietary technology with Bristol Myers Squibb’s strong development and global commercialization capabilities.
The deal strengthens Bristol Myers Squibb’s cancer treatment pipeline and adds a potential new option for solid tumors. For Janux, the partnership gives financial support, industry expertise, and a way to take its technology to a global market.
The agreement shows that big drug companies are eager to partner with biotech firms to access new cancer technologies, as competition in oncology research stays strong.
